VELDMAN et al. U.S. National Phase of PCT/IB2004/003886

AMENDMENTS TO THE CLAIMS

Amend the claims as follows

- 1. (Original) A pharmaceutical formulation comprising:
 - (i) a drug; and
 - (ii) a short-chain sphingolipid selected from compounds of the following formula:

wherein:

R¹ is independently:

an O-linked saccharide group; or

an O-linked polyhydric alcohol group;

or:

R¹ is independently:

an O-linked (optionally N-(C_{1-4} alkyl)-substituted amino)- C_{1-6} alkyl-

phosphate group; or

an O-linked (polyhydric alcohol-substituted)- C_{1-6} alkyl-phosphate

group;

R² is independently C₃₋₉alkyl,

VELDMAN et al. U.S. National Phase of PCT/IB2004/003886

and is independently unsubstituted or substituted;

R³ is independently C₇₋₁₉alkyl,

and is independently unsubstituted or substituted;

R⁴ is independently -H, -OH, or -O-C₁₋₄alkyl;

R^N is independently -H or C₁₋₄alkyl;

the bond marked with an alpha (α) is independently a single bond or a double bond;

if the bond marked with an alpha (α) is a double bond, then R⁵ is -H; if the bond marked with an alpha (α) is a single bond, then R⁵ is -H or -OH; the carbon atom marked (*) is independently in an R-configuration or an S-configuration;

the carbon atom marked (**) is independently in an R-configuration or an S-configuration;

and pharmaceutically acceptable salts, solvates, esters, ethers, chemically protected forms thereof.

Claims 2-91. (Cancelled)